Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Ulcerative Colitis: Update Bulletin [Feb 2016]

Product Code:
Publication Date:
February 2016

Gain new KOL insights on the latest events happening in Ulcerative Colitis. Topics covered include opinions regarding Phase III data on Johnson & Johnson’s Stelara (ustekinumab) in Crohn’s disease and the launch of a new study looking at use of the therapy in patients with UC; the recent filing in the US and EU for Amgen’s ABP 501 (a proposed adalimumab biosimilar); the FDA advisory committee’s decision to recommend approval of Celltrion’s CT-P13 (a proposed infliximab biosimilar); as well as opinions on the early development of both Qu Biologics’ QBECO and Protagonist Therapeutics’ PTG 100.

Key Questions Answered in this Update Bulletin:

  • How do KOLs perceive Stelara’s potential in the UC market?
  • How do KOLs perceive the potential of ABP 501 (a Humira biosimilar) in the UC marketplace?
  • What impact do they believe the arrival of biosimilar Humira will have on the market?
  • What do KOLs think of the so-called ‘switching trials,’ which see patients transitioned from an originator therapy to a biosimilar?
  • Do such trials boost confidence in prescribing biosimilars in UC?
  • What are KOLs’ opinions of an FDA committee’s decision to recommend approval of CT-P13, a biosimilar version of Janssen’s Remicade? 
  • What do KOLs think of the mechanism of action behind QBECO? 
  • Where in the treatment paradigm might QBECO be placed if approved?
  • How clinically attractive is Protagonist Therapeutics’ PTG 100?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved